|
Mar 7
|
Compugen Ltd. (NASDAQ:CGEN) Q4 2023 Earnings Call Transcript
|
|
Mar 6
|
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
|
|
Mar 6
|
Compugen Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Mar 5
|
Compugen Reports Fourth Quarter and Full Year 2023 Results
|
|
Feb 29
|
Is a Surprise Coming for Compugen (CGEN) This Earnings Season?
|
|
Feb 27
|
ACM Research (ACMR) to Report Q4 Earnings: What's in Store?
|
|
Feb 26
|
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
|
|
Dec 21
|
Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More
|
|
Dec 20
|
Gilead (GILD), Compugen Collaborate for Immunotherapy Program
|
|
Dec 20
|
Compugen (NASDAQ:CGEN) delivers shareholders impressive 144% return over 1 year, surging 158% in the last week alone
|
|
Dec 19
|
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
|
|
Dec 19
|
Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology
|
|
Dec 19
|
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
|
|
Dec 5
|
Is Compugen (CGEN) Outperforming Other Medical Stocks This Year?
|
|
Nov 8
|
Compugen Ltd. (NASDAQ:CGEN) Q3 2023 Earnings Call Transcript
|
|
Nov 7
|
Compugen Reports Third Quarter 2023 Results
|
|
Nov 6
|
Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy
|
|
Nov 3
|
Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification
|
|
Oct 3
|
Compugen to Present at Single Cell Genomics 2023 Meeting
|
|
Oct 2
|
Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer
|